Edenius holds a medical degree and has a PhD from the Karolinska Institute. She joined Medivir this month from Swedish pharmaceutical company Orexo, where she was senior vice president and chief scientific officer.
Prior to this, Edenius was vice president and chief scientific officer of Biolipox from 2001–2007 and held various executive positions in experimental medicine, Clinical R&D at AstraZeneca in Sweden.
Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.
Medivir appoints vp for r&d projects
Charlotte Edenius takes up newly created position
You may also like
Regulatory
FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment
The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline